Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/115580
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ruiz Sala, Pedro | en_US |
dc.contributor.author | Peña Quintana, Luis | en_US |
dc.date.accessioned | 2022-07-01T13:27:55Z | - |
dc.date.available | 2022-07-01T13:27:55Z | - |
dc.date.issued | 2021 | en_US |
dc.identifier.issn | 2077-0383 | en_US |
dc.identifier.uri | http://hdl.handle.net/10553/115580 | - |
dc.description.abstract | Mitochondrial fatty acid β-oxidation (FAO) contributes a large proportion to the body’s energy needs in fasting and in situations of metabolic stress. Most tissues use energy from fatty acids, particularly the heart, skeletal muscle and the liver. In the brain, ketone bodies formed from FAO in the liver are used as the main source of energy. The mitochondrial fatty acid oxidation disorders (FAODs), which include the carnitine system defects, constitute a group of diseases with several types and subtypes and with variable clinical spectrum and prognosis, from paucisymptomatic cases to more severe affectations, with a 5% rate of sudden death in childhood, and with fasting hypoketotic hypoglycemia frequently occurring. The implementation of newborn screening programs has resulted in new challenges in diagnosis, with the detection of new phenotypes as well as carriers and false positive cases. In this article, a review of the biochemical markers used for the diagnosis of FAODs is presented. The analysis of acylcarnitines by MS/MS contributes to improving the biochemical diagnosis, both in affected patients and in newborn screening, but acylglycines, organic acids, and other metabolites are also reported. Moreover, this review recommends caution, and outlines the differences in the interpretation of the biomarkers depending on age, clinical situation and types of samples or techniques. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Journal of Clinical Medicine | en_US |
dc.source | Journal of Clinical Medicine [2077-0383], v. 10(21):4855 (Octubre 2021) | en_US |
dc.subject | 32 Ciencias médicas | en_US |
dc.subject | 3201 Ciencias clínicas | en_US |
dc.subject | 320110 Pediatría | en_US |
dc.subject | 241108 Metabolismo humano | en_US |
dc.subject.other | Fatty acid β-oxidation diseases | en_US |
dc.subject.other | Carnitine | en_US |
dc.subject.other | Acylcarnitines | en_US |
dc.subject.other | Newborn screening | en_US |
dc.subject.other | Mass spectrometry | en_US |
dc.subject.other | Acylglycines | en_US |
dc.title | Biochemical markers for the diagnosis of mitochondrial fatty acid oxidation diseases | en_US |
dc.type | info:eu-repo/semantics/article | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.3390/jcm10214855 | en_US |
dc.contributor.orcid | 0000-001-6052-5894 | - |
dc.contributor.authorscopusid | 6603266503 | - |
dc.identifier.issue | 21 | - |
dc.relation.volume | 10 | en_US |
dc.investigacion | Ciencias de la Salud | en_US |
dc.type2 | Artículo | en_US |
dc.description.numberofpages | 26 | en_US |
dc.utils.revision | Sí | en_US |
dc.date.coverdate | Octubre 2021 | en_US |
dc.identifier.ulpgc | Sí | en_US |
dc.contributor.buulpgc | BU-MED | en_US |
dc.description.sjr | 1,04 | |
dc.description.jcr | 4,964 | |
dc.description.sjrq | Q1 | |
dc.description.jcrq | Q2 | |
dc.description.scie | SCIE | |
dc.description.miaricds | 10,5 | |
item.grantfulltext | open | - |
item.fulltext | Con texto completo | - |
crisitem.author.dept | GIR IUIBS: Nutrición | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.dept | Departamento de Ciencias Clínicas | - |
crisitem.author.orcid | 0000-0001-6052-5894 | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.fullName | Peña Quintana, Luis | - |
Appears in Collections: | Artículos |
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.